Dingdang Health Technology Group Ltd. disclosed that it repurchased 0.56 million ordinary shares on 9 October 2026, representing 0.05 % of its issued share capital (excluding treasury shares) as of the previous day. The shares were bought on the Hong Kong Stock Exchange at prices ranging from HKD 0.78 to HKD 0.85, with a volume-weighted average cost of HKD 0.8258 per share. The total consideration amounted to HKD 0.46 million.
Following the transaction, the company’s issued share count (excluding treasury shares) fell to 1.23 billion, while its treasury‐share balance increased to 7.34 million. The total number of issued shares, including treasury shares, remained unchanged at 1.24 billion.
The 9 October purchase was executed under the general mandate approved by shareholders on 23 June 2026, which authorizes the company to buy back up to 124.32 million shares. Cumulative repurchases since the mandate now stand at 10.20 million shares, equivalent to 0.82 % of the company’s issued share base on the mandate date.
In line with Hong Kong listing rules, Dingdang Health is subject to a moratorium on issuing new shares or disposing of treasury shares until 8 November 2026, unless prior approval is obtained from the exchange.
Comments